Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7795317 | 1.00 | HDAC1 (0.48) | HDAC1HDAC3HDAC4HDAC6ALDH1A1 | |
| SCHEMBL7801235 | 1.00 | HDAC1 (0.48) | HDAC1HDAC3HDAC4HDAC6ALDH1A1 | |
| SCHEMBL7789527 | 0.80 | HDAC1 (0.47) | HDAC1HDAC3HDAC4HDAC6NAMPT | |
| SCHEMBL1174109 | 0.79 | NAMPT (0.46) | HDAC1HDAC3HDAC4HDAC6ALDH1A1 | |
| SCHEMBL1174479 | 0.78 | HDAC1 (0.48) | HDAC1HDAC3HDAC4HDAC6ALDH1A1 | |
| SCHEMBL7797186 | 0.77 | HDAC6 (0.54) | HDAC1HDAC3HDAC4HDAC6ALDH1A1 | |
| SCHEMBL7796730 | 0.77 | HDAC6 (0.46) | HDAC1HDAC3HDAC4HDAC6ALDH1A1 | |
| SCHEMBL7801296 | 0.76 | HDAC6 (0.41) | HDAC1HDAC3HDAC6ALDH1A1MAPT | |
| SCHEMBL7799029 | 0.75 | NPC1 (0.52) | HDAC1HDAC3HDAC4HDAC6MAPT | |
| SCHEMBL12869062 | 0.75 | HDAC6 (0.39) | HDAC6ALDH1A1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2010151317-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | HDAC1 3/4885HDAC3 4/4885HDAC4 5/4885 |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | HDAC1 3/4885HDAC3 4/4885HDAC4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.